Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 6, 2012, Pages 936-943

  Soyka, Jan D ^a   Muster, Marco A ^a   Schmid, Daniel T ^a   Seifert, Burkhardt ^b   Schick, Ulrike ^c   Miralbell, Raymond ^c   Jorcano, Sandra ^d   Zaugg, Kathrin ^a   Seifert, Hans Helge ^a   Veit Haibach, Patrick ^a   Strobel, Klaus ^a   Schaefer, Niklaus G ^a   Husarik, Daniela B ^a   Hany, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d Instituto Oncologico Teknon   (Spain)

Author keywords

18F Choline PET CT; Clinical impact; Recurrent prostate cancer

Indexed keywords

CHOLINE; FLUORINE 18; FLUOROCHOLINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROMETHYLCHOLINE;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; RETROSPECTIVE STUDY; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; RECURRENT DISEASE; SCINTISCANNING;

ADULT; AGED; CHOLINE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84862653330     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2083-2     Document Type: Article

References (20)

1. A Jemal F Bray MM Center J Ferlay E Ward D Forman 2011 Global cancer statistics CA Cancer J Clin 61 69 90 10.3322/caac.20107 21296855 10.3322/caac.20107
2. GL Lu-Yao AL Potosky PC Albertsen JH Wasson MJ Barry JE Wennberg 1996 Follow-up prostate cancer treatments after radical prostatectomy: a population-based study J Natl Cancer Inst 88 166 173 8632490 10.1093/jnci/88.3-4.166 1:STN:280:DyaK283jtF2gsw%3D%3D
3. SR Bott 2004 Management of recurrent disease after radical prostatectomy Prostate Cancer Prostatic Dis 7 211 216 10.1038/sj.pcan.45007324500732 15278094 10.1038/sj.pcan.4500732 1:STN:280:DC%2BD2cvjslOrsw%3D%3D
4. FJ Fowler Jr MJ Barry G Lu-Yao A Roman J Wasson JE Wennberg 1993 Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993) Urology 42 622 629 8256394 10.1016/0090-4295(93)90524-E
5. SJ Freedland EB Humphreys LA Mangold M Eisenberger FJ Dorey PC Walsh, et al. 2005 Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 433 439 10.1001/jama.294.4.433 16046649 10.1001/jama.294.4.433 1:CAS:528:DC%2BD2MXms1ygsLk%3D
6. N Mottet J Bellmunt M Bolla S Joniau M Mason V Matveev, et al. 2011 EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 572 583 10.1016/j.eururo.2011. 01.025 21315502 10.1016/j.eururo.2011.01.025
7. A Heidenreich J Bellmunt M Bolla S Joniau M Mason V Matveev, et al. 2011 EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 61 71 10.1016/j.eururo.2010.10.039 21056534 10.1016/j.eururo.2010.10.039
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, prostate cancer. 2010. Fort Washington: National Comprehensive Cancer Network
9. DT Schmid H John R Zweifel T Cservenyak G Westera GW Goerres, et al. 2005 Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 623 628 10.1148/radiol.2352040494 15858102 10.1148/radiol. 2352040494
10. M Picchio A Briganti S Fanti A Heidenreich BJ Krause C Messa, et al. 2011 The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer Eur Urol 59 51 60 10.1016/j.eururo.2010.09.004 20869161 10.1016/j.eururo.2010.09.004
11. S Fanti B Krause W Weber P Castellucci AL Grosu IJ de Jong IJ, et al. 2011 Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83 Eur Urol 60 e37 e38 10.1016/j.eururo.2011.08.009 21855205 10.1016/j.eururo.2011.08.009 author reply e39-41
12. P Castellucci C Fuccio C Nanni I Santi A Rizzello F Lodi, et al. 2009 Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med 50 1394 1400 10.2967/jnumed.108.061507 19690023 10.2967/jnumed.108.061507
13. BJ Krause M Souvatzoglou M Tuncel K Herrmann AK Buck C Praus, et al. 2008 The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 18 23 10.1007/s00259-007-0581-4 17891394 10.1007/s00259-007-0581-4 1:CAS:528:DC%2BD2sXhsVSmtLbO
14. DB Husarik R Miralbell M Dubs H John OT Giger A Gelet, et al. 2008 Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 253 263 10.1007/s00259-007-0552-9 17926036 10.1007/s00259-007-0552-9
15. M Heinisch A Dirisamer W Loidl F Stoiber B Gruy S Haim, et al. 2006 Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 8 43 48 10.1007/s11307-005-0023-2 16315004 10.1007/s11307-005-0023- 2
16. P Castellucci C Fuccio D Rubello R Schiavina I Santi C Nanni, et al. 2011 Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 38 55 63 10.1007/s00259-010-1604-0 20848281 10.1007/s00259-010-1604-0
17. M Souvatzoglou BJ Krause A Purschel R Thamm T Schuster AK Buck, et al. 2011 Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer Radiother Oncol 99 193 200 10.1016/j.radonc.2011.05.005 21620494 10.1016/j.radonc.2011.05.005
18. F Wurschmidt C Petersen A Wahl J Dahle M Kretschmer 2011 [18F]Fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes Radiat Oncol 6 44 10.1186/1748-717X-6-44 21529377 10.1186/1748-717X-6-44
19. P Rigatti N Suardi A Briganti LF Da Pozzo M Tutolo L Villa, et al. 2011 Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography Eur Urol 60 935 943 10.1016/j.eururo.2011.07.060 21840116 10.1016/j.eururo.2011.07.060
20. SA Kwee H Wei I Sesterhenn D Yun MN Coel 2006 Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET J Nucl Med 47 262 269 16455632